Other symptoms include burning, stinging and itching. The inflammation from seborrheic dermatitis causes a disruption of the skin barrier on the scalp,” says Dr. Woolerry-Lloyd.

This article was originally published on Health. In addition to your body, hands, and face, eczema can also plague the scalp, usually in a condition known as seborrheic dermatitis.

The topical Janus kinase inhibitor ruxolitinib, 1.5%, (approved for atopic dermatitis and vitiligo) has also been reported to be effective for refractory facial SD.

A: Dandruff is a condition in which the skin on the scalp begins to flake and shed. It is often caused by a mild form of an inflammatory skin condition known as seborrheic dermatitis.

People with Parkinson’s often experience changes to their skin. Changes in the skin could include oiliness and red, itchy, flaky skin known as seborrheic dermatitis.

Also, it’s making my hair really dry. Dear Reader: Dandruff is a condition in which the skin on the scalp begins to flake and shed. It is often caused by a mild form of an inflammatory skin condition ...

Key takeaways: Malassezia yeast may not be the root cause of seborrheic dermatitis. A new study showed that Zoryve was a cosmetically pleasing treatment option for seborrheic dermatitis in diverse ...

Skin conditions are extremely common, but knowledge about them is not. We spoke to a dermatologist to clear up myths surrounding psoriasis, seborrheic dermatitis, and more.

Once-daily roflumilast foam 0.3% demonstrated safety and efficacy in the treatment of erythema, scaling and itching caused by seborrheic dermatitis, according to a phase 2a study.“Seborrheic ...

Isotretinoin for Seborrheic Dermatitis: A Review – An American Academy of Dermatology Reading Room selection October 17, 2023 • 1 min read American Academy of Dermatology staff DermWorld Weekly ...

Meeting Coverage > ISDS Topical PDE4 Inhibitor Impresses in Trial of Seborrheic Dermatitis — Rapid, persistent improvement in body surface area, itch, other symptoms with roflumilast by Charles ...

The US Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for roflumilast foam 0.3% for treating seborrheic dermatitis in patients ages 9 years and older. If ...